StockpollyBeta
Get App
Delisting riskPopularity #4,921
ELUT · NASDAQ · Biotechnology

Elutia (ELUT)

Develops drug-eluting biomatrices for surgical reconstruction and implanted-device complications.

$0.8102
After-hours close0.00 (0.00%)
At close$0.8102(−5.06%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue667665663332
Cost of revenue344333431111
Gross profit323332232221
10111111131110136789
Research & development111111111123
678887775165
Selling & marketing333333342−311
General & administrative345554444443
Other expenses432253340502
Operating income−7−9−8−9−10−8−8−10−4−5−6−8
−1−7−10−2012−1404−1−20
Interest income000000000000
Interest expense121111110−400
Other non-operating income05819−130−5−1−4520
Income before tax−9−15−18−281−9−4−100−7−8−8
Income tax expense000000000000
Net income from continuing operations−9−15−18−281−9−4−100−7−8−8
Discontinued operations−16000000−37700
Net income−10−9−18−281−9−4−10−471−7−8
EPS, basic−$0.57−$0.66−$0.75−$1.13−$0.36−$0.26−$0.10−$0.23−$0.01$1.66−$0.17−$0.18
EPS, diluted−$0.57−$0.66−$0.75−$1.13−$0.33−$0.26−$0.21−$0.26−$0.19$1.48−$0.17−$0.18
Weighted average shares, basic172324253335394241434344
Weighted average shares, diluted172324253635434645474344
EBITDA−6−13−16−263−7−2−81−10−8−7
Depreciation & amortization111111111000
EBIT−7−14−17−272−8−3−90−10−8−8